Bovilis Bovipast RSP suspension for injection for cattle

国家: 爱尔兰

语言: 英文

来源: HPRA (Health Products Regulatory Authority)

有效成分:

Inactivated bovine respiratory syncytial virus strain ev908; Inactivated Parainfluenza-3-virus, strain SF-4 Reisinger; Inactivated mannheimia (pasteurella) haemolyticaA1, strain M4/1

可用日期:

Intervet Ireland Limited

ATC代码:

QI02AL04

INN（国际名称）:

Inactivated bovine respiratory syncytial virus strain ev908; Inactivated Parainfluenza-3-virus, strain SF-4 Reisinger; Inactivated mannheimia (pasteurella) haemolyticaA1, strain M4/1

剂量:

.

药物剂型:

Suspension for injection

处方类型:

POM (E): Prescription Only Exempt as defined in relevant national legislation

治疗组:

Cattle

治疗领域:

bovine parainfluenza virus + bovine respiratory syncytial virus + pasteurella

疗效迹象:

Immunological - Inactivated Vaccine

授权状态:

Authorised

授权日期:

2000-06-06

产品特点

Registration file / April 2022
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Bovilis Bovipast
RSP, suspension for injection for cattle.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose (5 ml) contains:
ACTIVE SUBSTANCES:
Inactivated Bovine Respiratory Syncytial virus, strain EV908
10
4.77
– 10
5.45
U/dose
*
Inactivated Parainfluenza-3Virus, strain SF-4 Reisinger
10
3.54
– 10
4.85
U/dose
*
Inactivated
_Mannheimia haemolytica _
A1
_, _
strain M4/1
_ _
10
4.24
– 10
5.00
U/dose
*
*Results obtained with AlphaLISA assays
ADJUVANTS:
Aluminium hydroxide
37.5
mg
Quil A (Saponin)
0.189 – 0.791 mg
EXCIPIENTS:
Thiomersal
0.032 – 0.058 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for injection.
The product is pale yellow to red-pink with whitish sediment. By
shaking the sediment is easily
suspended to an opaque, whitish to red/pink suspension.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the active immunisation of cattle against:
- Parainfluenza-3 virus, to reduce infection,
- Bovine Respiratory Syncytial virus, to reduce infection and clinical
signs,
-
_Mannheimia haemolytica _
serotype A1, to reduce infection, mortality, clinical signs, lung
lesions and
bacterial invasion of the lung caused by serotypes A1 and A6.
Cross-reactive immunity to the A6 serotype of
_Mannheimia haemolytica_
has been demonstrated in a
challenge experiment under laboratory conditions after primary course
of vaccination.
Approximately two weeks after completion of the basic immunisation
programme, the humoral
immune response against Bovine Respiratory Syncytial virus and
Parainfluenza-3 virus is at its highest
level. The duration of protective immunity has not been established in
challenge experiments.
Onset of immunity: 2 weeks.
Duration of immunity: not established.
4.3
CONTRAINDICATIONS
Registration file / April 2022
Do not vaccinate animals that have intercurrent disease, heavy
parasitic infestation or are in poor
general condit